Skip to content

Study · Animal study (in vivo) · mouse · 2011

6 results

Exendin-4, a glucagon-like peptide-1 receptor agonist, provides neuroprotection in mice transient focal cerebral ischemia.

Teramoto S, Miyamoto N, Yatomi K, Tanaka Y, Oishi H, Arai H, Hattori N, Urabe T

Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism13 Apr 2011Cited by 170 (Europe PMC)

PMID21487412 (opens in a new tab)PMCIDPMC3170947 (opens in a new tab)DOI10.1038/jcbfm.2011.51 (opens in a new tab)PepBankPUB-21487412
Read at sourcePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study6

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mice with cerebral ischemia, exendin‑4 reduced infarct volume compared with vehicle.

    In plain wordsIn mice with cerebral ischemia, exendin‑4 reduced infarct volume compared with vehicle.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseInfarct volume
    Study

    mousen: not reported in source

    focal cerebral ischemia-reperfusion
    Comparator
    vehicle
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated · transvenousAs given in this study (mouse).

    Source sentences

    Summary
    Exendin-4 treatment significantly reduced infarct volume and improved functional deficit.
    1 context sentence
    Summary · context
    Mice received a transvenous injection of exendin-4, after a 60-minute focal cerebral ischemia.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In mice with cerebral ischemia, exendin‑4 improved functional deficit compared with vehicle.

    In plain wordsIn mice with cerebral ischemia, exendin‑4 improved functional deficit compared with vehicle.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseFunctional deficit
    Study

    mousen: not reported in source

    focal cerebral ischemia-reperfusion
    Comparator
    vehicle
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated · transvenousAs given in this study (mouse).

    Source sentences

    Summary
    Exendin-4 treatment significantly reduced infarct volume and improved functional deficit.
    1 context sentence
    Summary · context
    Mice received a transvenous injection of exendin-4, after a 60-minute focal cerebral ischemia.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In mice, exendin‑4 suppressed oxidative stress, inflammation, and cell death after reperfusion compared with vehicle.

    In plain wordsIn mice, exendin‑4 suppressed oxidative stress, inflammation, and cell death after reperfusion compared with vehicle.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseReperfusion injury response
    Study

    mousen: not reported in source

    focal cerebral ischemia-reperfusion
    Comparator
    vehicle
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated · transvenousAs given in this study (mouse).

    Source sentences

    Summary
    It also significantly suppressed oxidative stress, inflammatory response, and cell death after reperfusion.
    1 context sentence
    Summary · context
    Mice received a transvenous injection of exendin-4, after a 60-minute focal cerebral ischemia.
  4. 04AnimalAnimal study (in vivo)Mechanism

    In mice, intracellular cAMP was slightly higher with exendin‑4 than with vehicle.

    In plain wordsIn mice, intracellular cAMP was slightly higher with exendin‑4 than with vehicle.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseIntracellular cAMP
    Study

    mousen: not reported in source

    focal cerebral ischemia-reperfusion
    Comparator
    vehicle
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated · transvenousAs given in this study (mouse).

    Source sentences

    Summary
    Furthermore, intracellular cyclic AMP (cAMP) levels were slightly higher in the exendin-4 group than in the vehicle group.
    1 context sentence
    Summary · context
    Mice received a transvenous injection of exendin-4, after a 60-minute focal cerebral ischemia.

Studies that did not test the peptide alone2

In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Exenatide (exendin-4).

  1. 05AnimalNot a test of Exenatide (exendin-4) aloneAnimal study (in vivo)Efficacy outcome

    In mice, insulin levels showed no serial changes in either the exendin‑4 or vehicle group.

    In plain wordsIn mice, insulin levels did not change over time in either the exendin‑4 or vehicle group.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeInsulin levels
    Study

    mousen: not reported in source

    focal cerebral ischemia-reperfusion
    Comparator
    vehicle
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    No serial changes were noted in insulin and glucose levels in both groups.
    1 context sentence
    Summary · context
    Mice received a transvenous injection of exendin-4, after a 60-minute focal cerebral ischemia.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  2. 06AnimalNot a test of Exenatide (exendin-4) aloneAnimal study (in vivo)Efficacy outcome

    In mice, glucose levels showed no serial changes in either the exendin‑4 or vehicle group.

    In plain wordsIn mice, glucose levels did not change over time in either the exendin‑4 or vehicle group.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeGlucose levels
    Study

    mousen: not reported in source

    focal cerebral ischemia-reperfusion
    Comparator
    vehicle
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    No serial changes were noted in insulin and glucose levels in both groups.
    1 context sentence
    Summary · context
    Mice received a transvenous injection of exendin-4, after a 60-minute focal cerebral ischemia.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.